Current Lung Cancer Management and Return-to-Duty Considerations for Military Aircrew.

While there is an opportunity to update current waiver policies for resectable early-stage lung cancer, additional considerations are still required to individualize aeromedical decision-making based on underlying cancer histology, treatment response, side effects of newer therapies, and risk of cancer recurrence after remission. In preserving their fitness for duty, emerging evidence and the continuously evolving treatment landscape will continue to challenge flight surgeons to keep aircrew well-informed of their management options. Low JW. Current lung cancer management and return-to-duty considerations for military aircrew. Aerosp Med Hum Perform. 2026; 97(3):185-193.